Dermatologists may choose from various conventional and biological systemic agents to
treat patients with moderate‐to‐severe psoriasis. We set out to analyse systematically the …

Psoriasis as a chronic inflammatory disease often requires effective long-term treatment; a
comprehensive systematic evaluation of efficacy and safety of systemic long-term treatments …

Background The comparative efficacy and tolerability of conventional and biologic
treatments for moderate‐to‐severe plaque psoriasis are unknown. Objectives To perform a …

What is known and Objective Psoriasis is a chronic skin disease for which there is an
increasing range of treatment options. Biological agents (ustekinumab, adalimumab …

Background Ustekinumab, a novel monoclonal antibody for the treatment of moderate to
severe plaque‐type psoriasis, has recently received regulatory approval in Europe, bringing …

Background Multiple biological therapies are approved for the treatment of moderate‐to‐
severe psoriasis. Objectives To assess the short‐term efficacy of biological treatments for …

Background Approximately 2% of people worldwide have psoriasis, with as many as 1
million people with psoriasis in Canada alone. 1, 2 The severity of psoriasis ranges from …

Background Despite the chronicity of psoriasis, most systematic reviews focus on short‐term
treatment. Methods The systematic search strategy and results from the German Psoriasis …

Aims: To compare the efficacy of psoriasis treatments through a systematic literature review
and meta-analysis. Methods: Randomized controlled trials evaluating the Psoriasis Area …

Background: Psoriasis is a chronic, immune-mediated skin disease that also has systemic
manifestations. Safe and effective long-term treatments are needed. Biologic treatments that …